Fulvestrant Injection
Product Images NDC 0781-9055

View Photos of Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 16 technical images submitted to the FDA as part of the official labeling for Fulvestrant (NDC 0781-9055). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Sandoz Inc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Figure-1 (Fulvestrant Room Nvp 01)

FDA Label Image

Figure-2 (Fulvestrant Room Nvp 02)

FDA Label Image

Figure 3.jpg (Fulvestrant Room Nvp 03)

FDA Label Image

Figure 4.jpg (Fulvestrant Room Nvp 04)

FDA Label Image

Figure 5.jpg (Fulvestrant Room Nvp 05)

FDA Label Image

Structural Formula (Fulvestrant Room Nvp 06)

FDA Label Image

Figure 6.jpg (Fulvestrant Room Nvp 07)

Figure 6.jpg (Fulvestrant Room Nvp 07)
Proportion of patients progression free and the Progression Free Survival (ITT Population) was evaluated for two doses of Fulvestrant: 250 mg and 500 mg. The number of patients at risk were 374 for Fulvestrant 250 mg and 362 for Fulvestrant 500 mg. The time in months was also provided.*
FDA Label Image

Figure 7.jpg (Fulvestrant Room Nvp 08)

FDA Label Image

Figure 8.jpg (Fulvestrant Room Nvp 09)

FDA Label Image

Figure-9 (Fulvestrant Room Nvp 10)

FDA Label Image

Figure-10 (Fulvestrant Room Nvp 11)

FDA Label Image

Figure 11.jpg (Fulvestrant Room Nvp 12)

FDA Label Image

Figure 12.jpg (Fulvestrant Room Nvp 13)

FDA Label Image

Fig_13.jpg (Fulvestrant Room Nvp 14)

FDA Label Image

Fig_14.jpg (Fulvestrant Room Nvp 15)

FDA Label Image

Carton (Fulvestrant Room Nvp 16)

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.